ATX Stock Overview
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia.
Notes are coming soon
Amplia Therapeutics Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.086|
|52 Week High||AU$0.18|
|52 Week Low||AU$0.08|
|1 Month Change||4.88%|
|3 Month Change||-13.13%|
|1 Year Change||-47.88%|
|3 Year Change||21.13%|
|5 Year Change||-71.33%|
|Change since IPO||-95.70%|
Recent News & Updates
We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth CarefullyJan 13
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In GrowthApr 28
Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their HoldingsFeb 28
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In GrowthJan 06
|ATX||AU Biotechs||AU Market|
Return vs Industry: ATX underperformed the Australian Biotechs industry which returned 17.9% over the past year.
Return vs Market: ATX underperformed the Australian Market which returned 2.2% over the past year.
|ATX Average Weekly Movement||6.9%|
|Biotechs Industry Average Movement||8.9%|
|Market Average Movement||8.5%|
|10% most volatile stocks in AU Market||15.5%|
|10% least volatile stocks in AU Market||3.4%|
Stable Share Price: ATX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ATX's weekly volatility (7%) has been stable over the past year.
About the Company
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company’s product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney.
Amplia Therapeutics Limited Fundamentals Summary
|ATX fundamental statistics|
Is ATX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ATX income statement (TTM)|
|Cost of Revenue||AU$182.52k|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.027|
|Net Profit Margin||-175.02%|
How did ATX perform over the long term?See historical performance and comparison